FEATURED IN INDUSTRY NEWS
- Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon
- Orange County Ambulance Company Donates $400,000 to NAEMT During ‘EMS Week’
- NEW VICE PRESIDENT OF SALES AT KUSSMAUL ELECTRONICS
- Aeromedevac Air Ambulance Announces Extended Air Ambulance Service and Medical Flights to and from Mexico
- DOG DAYS: LIFE EMS AMBULANCE TEAMS WITH PAWS WITH A CAUSE® TO ACCLIMATE ASSISTANCE DOGS-IN-TRAINING TO EMERGENCY SITUATIONS
- NAEMT & NEMSMA Announce Strategic Partnership
- American Academy of Pediatrics and National Association of Emergency Medical Technicians to Collaborate to Improve Pediatric Emergency Care
San Antonio, Texas -- Every year, over 5 million central venous lines to establish vascular access are placed in patients, many in resuscitation attempts, at an average cost of just under $300 per procedure, and an average procedure time as high as 15 minutes. In comparison, intraosseous access, which establishes vascular access through the inside of the bones, accomplishes the same function safely and effectively, in 90 seconds, and at a cost of just over $100 per insertion, a study recently found.
The results of the study “Intraosseous vascular access can be used safely and effectively, and at a lower cost than central venous catheters, for pediatric and adult patients in the hospital setting,” were presented at the American College of Emergency Physicians on October 18 by Michael Dolister, MD with research support from the Science and Clinical team from Vidacare Corporation, makers of the EZ-IO® Intraosseous Infusion System. The study examined whether IO access enabled fluid and drug delivery in a manner comparable to central venous catheters and increased the rate of return of spontaneous circulation (ROSC). The 50-patient study found:
• Success rate of 96% in establishing vascular access on first attempt;
• Mean time to vascular access using IO route of 95 seconds;
• Of patients in cardiac/arrest, 52% returned to spontaneous circulation;
• A savings of $190 per case compared to cost of central venous lines (CVLs) (excluding ultrasound guidance and assuming no complications).*
The study concluded that, “…IO access in place of, or as a bridge to, central venous catheters is a safe, fast, and effective mode of vascular access for adult and pediatric patients in the hospital setting, with substantial cost savings potential.”
“This study proves that IO access is as safe, fast and effective as central venous catheters, and can be substantially less expensive. If we replaced just ten percent of the estimated five million CVLs with IO, it could mean a savings of as much as $95 million annually to the healthcare system,” said Michael Voss, Vidacare’s Chief Operating Officer.
Vidacare’s EZ-IO should be used anytime in which vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. As with any vascular access site, the IO insertion site should be monitored frequently. IO should only be used when landmarks can be clearly identified.
Vidacare’s EZ-IO® Intraosseous Infusion System, the market leader in IO technology, provides immediate vascular access for patients in multiple clinical settings, using the intraosseous (inside the bone) space. The EZ-IO is used by 90 percent of US advanced life support ambulances and over half of US Emergency Departments, as well as the US Military.
Established in 2001, Vidacare Corporation is the pioneer of a broad technology platform for use in the field of intraosseous medicine. Current products include the EZ-IO® Intraosseous Infusion System, the OnControl™ Bone Marrow System and the OnControl™ Bone Access System. Applications include vascular access, emergency and disaster medicine, oncology and spinal surgery. Vidacare’s focus on enhancing clinical efficacy, patient safety and comfort, and reducing complications and their associated costs, has resulted in its devices becoming the recognized technology standard. Privately held, the company is based in San Antonio, Texas, and its products are marketed in over 50 countries worldwide. www.vidacare.com
###
*Research sponsored by Vidacare Corporation
